Compare Stocks: PRTA, SNDX, XNCR, and ANAB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$58.44 +1.2%	$58.54	$11.40 ▼ $72.36	$1.71B	0.72	405,996 shs	627,030 shs
PRTA Prothena	$9.39 -0.6%	$9.00	$7.73 ▼ $11.80	$494.74M	-0.3	466,172 shs	248,124 shs
SNDX Syndax Pharmaceuticals	$19.57 -0.4%	$20.85	$12.99 ▼ $25.59	$1.74B	0.4	1.38 million shs	1.44 million shs
XNCR Xencor	$29.00 +4.3%	$18.56	$7.71 ▼ $29.42	$2.07B	0.85	1.17 million shs	1.05 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+1.21%	-2.09%	+7.92%	+1.16%	+189.02%
PRTA Prothena	-0.63%	+5.74%	+7.31%	-6.66%	+7.07%
SNDX Syndax Pharmaceuticals	-0.41%	-0.96%	-5.96%	-1.66%	+20.50%
XNCR Xencor	+4.32%	+25.43%	+49.18%	+149.36%	+244.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANAB AnaptysBio	$58.44 +1.2%	$58.54	$11.40 ▼ $72.36	$1.71B	0.72	405,996 shs	627,030 shs
PRTA Prothena	$9.39 -0.6%	$9.00	$7.73 ▼ $11.80	$494.74M	-0.3	466,172 shs	248,124 shs
SNDX Syndax Pharmaceuticals	$19.57 -0.4%	$20.85	$12.99 ▼ $25.59	$1.74B	0.4	1.38 million shs	1.44 million shs
XNCR Xencor	$29.00 +4.3%	$18.56	$7.71 ▼ $29.42	$2.07B	0.85	1.17 million shs	1.05 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANAB AnaptysBio	+1.21%	-2.09%	+7.92%	+1.16%	+189.02%
PRTA Prothena	-0.63%	+5.74%	+7.31%	-6.66%	+7.07%
SNDX Syndax Pharmaceuticals	-0.41%	-0.96%	-5.96%	-1.66%	+20.50%
XNCR Xencor	+4.32%	+25.43%	+49.18%	+149.36%	+244.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANAB AnaptysBio	2.67	Moderate Buy	$82.00	40.31% Upside
PRTA Prothena	2.75	Moderate Buy	$23.75	152.93% Upside
SNDX Syndax Pharmaceuticals	2.85	Moderate Buy	$41.55	112.29% Upside
XNCR Xencor	2.44	Hold	$24.86	-14.29% Downside

Current Analyst Ratings Breakdown

Latest PRTA, SNDX, XNCR, and ANAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	ANAB AnaptysBio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$95.00
8/21/2026	SNDX Syndax Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/21/2026	SNDX Syndax Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$37.00 ➝ $33.00
8/11/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	SNDX Syndax Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$44.00 ➝ $40.00
8/7/2026	ANAB AnaptysBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/6/2026	XNCR Xencor	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$19.00 ➝ $20.00
8/6/2026	XNCR Xencor	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$26.00 ➝ $30.00
8/6/2026	XNCR Xencor	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$43.00 ➝ $44.00
8/5/2026	SNDX Syndax Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/5/2026	SNDX Syndax Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$40.00 ➝ $38.00

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANAB AnaptysBio	$234.60M	7.38	N/A	N/A	$1.34 per share	43.61
PRTA Prothena	$54.53M	9.02	N/A	N/A	$5.21 per share	1.80
SNDX Syndax Pharmaceuticals	$172.35M	10.06	N/A	N/A	$0.74 per share	26.45
XNCR Xencor	$125.58M	17.17	N/A	N/A	$8.90 per share	3.26

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANAB AnaptysBio	-$13.23M	-$1.08	N/A	17.98	N/A	-11.53%	N/A	-7.75%	11/10/2026 (Estimated)
PRTA Prothena	-$244.09M	-$0.84	N/A	N/A	3.33	-80.68%	-16.45%	-14.51%	11/5/2026 (Estimated)
SNDX Syndax Pharmaceuticals	-$285.42M	-$2.51	N/A	N/A	N/A	-87.52%	-372.94%	-39.11%	11/2/2026 (Estimated)
XNCR Xencor	-$91.92M	-$2.17	N/A	N/A	N/A	-155.59%	-28.66%	-20.38%	11/4/2026 (Estimated)

Latest PRTA, SNDX, XNCR, and ANAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million
8/5/2026	Q2 2026	XNCR Xencor	-$0.8015	-$0.29	+$0.5115	-$0.29	$18.89 million	$51.22 million
8/4/2026	Q2 2026	SNDX Syndax Pharmaceuticals	-$0.4477	-$0.55	-$0.1023	-$0.55	$79.36 million	$72.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANAB AnaptysBio	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XNCR Xencor	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANAB AnaptysBio	N/A	7.58	7.58
PRTA Prothena	N/A	25.05	25.05
SNDX Syndax Pharmaceuticals	38.95	6.77	6.44
XNCR Xencor	N/A	6.39	6.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANAB AnaptysBio	N/A
PRTA Prothena	97.08%
SNDX Syndax Pharmaceuticals	N/A
XNCR Xencor	N/A

Insider Ownership

Company	Insider Ownership
ANAB AnaptysBio	31.50%
PRTA Prothena	10.40%
SNDX Syndax Pharmaceuticals	4.80%
XNCR Xencor	5.08%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANAB AnaptysBio	100	29.61 million	20.28 million	Optionable
PRTA Prothena	130	52.35 million	46.91 million	Optionable
SNDX Syndax Pharmaceuticals	110	88.61 million	84.36 million	Optionable
XNCR Xencor	280	74.35 million	70.58 million	Optionable

PRTA, SNDX, XNCR, and ANAB Headlines

Recent News About These Companies

Xencor (NASDAQ:XNCR) Reaches New 52-Week High - Here's Why

August 24 at 12:59 PM | marketbeat.com

103,736 Shares in Xencor, Inc. $XNCR Bought by DCF Advisers LLC

August 20, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Hits A Fresh High: What Comes Next?

August 18, 2026 | kalkinemedia.comK

Xencor (NASDAQ:XNCR) Sets New 52-Week High - Should You Buy?

August 18, 2026 | marketbeat.com

Johnson & Johnson Purchases New Shares in Xencor, Inc. $XNCR

August 16, 2026 | marketbeat.com

Xencor, Inc. (XNCR) Stock Major Holders - Yahoo Finance

August 12, 2026 | finance.yahoo.com

Xencor (NASDAQ:XNCR) Hits New 1-Year High - Here's What Happened

August 12, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Xencor (XNCR), Alpha Teknova (TKNO) and Solventum Corporation (SOLV)

August 11, 2026 | theglobeandmail.com

Xencor (NASDAQ:XNCR) Stock Rating Upgraded by Wall Street Zen

August 8, 2026 | marketbeat.com

Xencor: Q2 Earnings Snapshot

August 7, 2026 | sfgate.com

RBC Capital Sticks to Their Buy Rating for Xencor (XNCR)

August 7, 2026 | theglobeandmail.com

Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Hold" by Brokerages

August 7, 2026 | marketbeat.com

Xencor Reports Second Quarter 2026 Financial Results

August 7, 2026 | aol.comA

Xencor (NASDAQ:XNCR) Price Target Raised to $30.00

August 6, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Hits New 52-Week High Following Better-Than-Expected Earnings

August 6, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Price Target Raised to $44.00 at Cantor Fitzgerald

August 6, 2026 | marketbeat.com

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

August 5, 2026 | zacks.com

Xencor (NASDAQ:XNCR) Releases Earnings Results, Beats Expectations By $0.51 EPS

August 5, 2026 | marketbeat.com

Xencor (NASDAQ:XNCR) Trading Down 3.9% - Here's Why

August 3, 2026 | marketbeat.com

Xencor’s XmAb412 Enters First-in-Human Testing: What Early-Stage Investors Should Watch

August 3, 2026 | tipranks.com

Xencor (NASDAQ:XNCR) Reaches New 1-Year High - Should You Buy?

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA, SNDX, XNCR, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

$58.44 +0.70 (+1.21%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$58.14 -0.30 (-0.52%)

As of 08:23 AM Eastern

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Prothena NASDAQ:PRTA

$9.39 -0.06 (-0.63%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$9.35 -0.04 (-0.43%)

As of 08:21 AM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Syndax Pharmaceuticals NASDAQ:SNDX

$19.57 -0.08 (-0.41%)

As of 08/24/2026 04:00 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Xencor NASDAQ:XNCR

$29.00 +1.20 (+4.32%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$29.00 0.00 (-0.01%)

As of 08:30 AM Eastern

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRTA, SNDX, XNCR, and ANAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRTA, SNDX, XNCR, and ANAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRTA, SNDX, XNCR, and ANAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA, SNDX, XNCR, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

Prothena NASDAQ:PRTA

Syndax Pharmaceuticals NASDAQ:SNDX

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRTA, SNDX, XNCR, and ANAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRTA, SNDX, XNCR, and ANAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRTA, SNDX, XNCR, and ANAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA, SNDX, XNCR, and ANAB Company Descriptions

AnaptysBio NASDAQ:ANAB

Prothena NASDAQ:PRTA

Syndax Pharmaceuticals NASDAQ:SNDX

Xencor NASDAQ:XNCR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools